Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 4/20 | 0.52 |
| ▸ | KDR | P35968 | 3/20 | 0.52 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.49 |
| ▸ | MET | P08581 | 9/20 | 0.46 |
| ▸ | AXL | P30530 | 4/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30697769 | 1.00 | PDGFRA (0.52) | PDGFRAKDRFGFR2METAXL | |
| SCHEMBL13936618 | 0.96 | PDGFRA (0.52) | PDGFRAKDRFGFR2METAXL | |
| SCHEMBL22009936 | 0.92 | PDGFRA (0.56) | PDGFRAKDRFGFR2METAXL | |
| SCHEMBL29487188 | 0.91 | PDGFRA (0.59) | PDGFRAKDRFGFR2METAXL | |
| SCHEMBL174159 | 0.91 | PDGFRA (0.59) | PDGFRAKDRFGFR2METAXL | |
| SCHEMBL20032552 | 0.88 | PDGFRA (0.51) | PDGFRAKDRFGFR2METAXL | |
| SCHEMBL22960033 | 0.85 | KDR (0.50) | PDGFRAKDRFGFR2METAXL | |
| SCHEMBL29487138 | 0.85 | KDR (0.50) | PDGFRAKDRFGFR2METAXL | |
| SCHEMBL20032555 | 0.85 | PDGFRA (0.53) | PDGFRAKDRFGFR2METAXL | |
| SCHEMBL1133098 | 0.85 | AXL (0.59) | PDGFRAKDRMETAXLSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025096463-A1 | PLK4 MODULATORS | VIBLIOME THERAPEUTICS, LLC (US) | 2025-05-08 | — | — | WO | disclosed |
| CN-117362275-A | Tyrosine protein kinase inhibitor and application thereof | 广州百霆医药科技有限公司 | 2024-01-09 | — | — | CN | disclosed |
| WO-2024000615-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND USE THEREOF | 广州百霆医药科技有限公司 | 2024-01-04 | — | — | WO | disclosed |
| EP-3329918-B1 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2022-05-25 | — | — | EP | disclosed |
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20200392110-A1 | QUINOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-12-17 | — | — | US | disclosed |
| EP-3415501-B9 | QUINOLINE DERIVATIVE | ONO PHARMACEUTICAL CO (JP) | 2020-12-02 | — | — | EP | disclosed |
| US-20200331860-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2020-10-22 | — | — | US | disclosed |
| US-10676462-B2 | Quinoline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-06-09 | — | — | US | disclosed |
| WO-2007033196-A1 | MET KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-22 | — | — | WO | disclosed |
| US-20070060613-A1 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-15 | — | — | US | disclosed |
| US-20070060613-A1 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-15 | — | — | US | disclosed |
| US-20070060613-A1 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-15 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| WO-2006108059-A1 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2006-10-12 | — | — | WO | disclosed |
| EP-1673085-A2 | C-MET MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005030140-A2 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331860-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | PDGFRA 63/4885KDR 4/4885FGFR2 590/4885 |
| US-20070054928-A1 | c-Met modulators and methods of use | FLT4, FLT1, MET | PDGFRA 63/4885KDR 4/4885FGFR2 590/4885 |
| US-20200392110-A1 | QUINOLINE DERIVATIVE | FLT3, AXL, ERBB2 | PDGFRA 155/4885KDR 27/4885FGFR2 365/4885 |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | FLT4, FLT1, MET | PDGFRA 63/4885KDR 4/4885FGFR2 590/4885 |
| US-11124482-B2 | C-met modulators and methods of use | FLT4, FLT1, MET | PDGFRA 63/4885KDR 4/4885FGFR2 590/4885 |
| US-10676462-B2 | Quinoline derivative | FLT3, AXL, ERBB2 | PDGFRA 155/4885KDR 27/4885FGFR2 365/4885 |
| US-20070060613-A1 | Met kinase inhibitors | MET, ERBB2, ABL1 | PDGFRA 318/4885KDR 212/4885FGFR2 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.